BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026

Reuters01-12

Jan 11 (Reuters) - Zymeworks Inc ZYME.O:

ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026
ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, & CHINA
ZYMEWORKS INC: GLOBAL PHASE 1 CLINICAL TRIAL INVESTIGATING ZW191 IN SOLID TUMORS IS ONGOING WITH DOSE OPTIMIZATION OF ZW191 IN OVARIAN CANCER

Source text: ID:nGNXcMtqc

Further company coverage: ZYME.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602563459?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 07:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602563459","market":"nz","top_or_hot":-1,"title":"BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Zymeworks Inc <span>ZYME.O</span>:</p><ul><li><p>ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026</p></li><li><p>ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, &amp; CHINA</p></li><li><p>ZYMEWORKS INC: GLOBAL PHASE 1 CLINICAL TRIAL INVESTIGATING ZW191 IN SOLID TUMORS IS ONGOING WITH DOSE OPTIMIZATION OF ZW191 IN OVARIAN CANCER</p></li></ul><p>Source text: <span>ID:nGNXcMtqc</span></p><p>Further company coverage: <span>ZYME.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 07:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026</title></head><body><p><span>Jan 11 (Reuters)</span><span> - </span>Zymeworks Inc <span>ZYME.O</span>:</p><ul><li><p>ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026</p></li><li><p>ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, &amp; CHINA</p></li><li><p>ZYMEWORKS INC: GLOBAL PHASE 1 CLINICAL TRIAL INVESTIGATING ZW191 IN SOLID TUMORS IS ONGOING WITH DOSE OPTIMIZATION OF ZW191 IN OVARIAN CANCER</p></li></ul><p>Source text: <span>ID:nGNXcMtqc</span></p><p>Further company coverage: <span>ZYME.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA4QRWPS:1","article_id":"2602563459","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602563459","pubTimestamp":1768172621,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026Jan 11 (Reuters) - Zymeworks Inc ZYME.O:ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026ZYMEWORKS: UP TO $440 MILLION IN M","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ZYME":"ZYMEWORKS INC (US)"},"translate_title":"简介-Zymeworks概述了2026年的战略重点和展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZYME":0.9},"content_text":"BRIEF-Zymeworks Outlines Strategic Priorities And Outlook For 2026Jan 11 (Reuters) - Zymeworks Inc ZYME.O:ZYMEWORKS OUTLINES STRATEGIC PRIORITIES AND OUTLOOK FOR 2026ZYMEWORKS: UP TO $440 MILLION IN MILESTONE PAYMENTS ELIGIBLE TO BE EARNED RELATED TO REGULATORY APPROVALS OF ZIIHERA IN GEA IN UNITED STATES, EUROPE, JAPAN, & CHINAZYMEWORKS INC: GLOBAL PHASE 1 CLINICAL TRIAL INVESTIGATING ZW191 IN SOLID TUMORS IS ONGOING WITH DOSE OPTIMIZATION OF ZW191 IN OVARIAN CANCERSource text: ID:nGNXcMtqcFurther company coverage: ZYME.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602563459","isCrawlerRequest":true}